No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Revive Therapeutics Ltd: MDA EN
Revive Therapeutics Ltd: AUDITED ANNUAL FINANCIAL STATEMENTS EN
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillami...
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID